complete primary vaccine series - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.45 [0.19, 1.05]< 10%1 study (-/1)96.8 %NAnot evaluable crucial-
deaths (time to event analysis only) 0.45 [0.19, 1.05]< 10%1 study (-/1)96.8 %NAnot evaluable crucial-
clinical deterioration 0.44 [0.37, 0.52]< 10%1 study (-/1)100.0 %NAnot evaluable important-
confirmed COVID (any severity) 0.43 [0.28, 0.66]< 193%5 studies (-/5)100.0 %NAnot evaluable important-
hospitalization 0.21 [0.12, 0.35]< 190%3 studies (-/3)100.0 %NAnot evaluable important-
symptomatic Covid-19 0.56 [0.41, 0.77]< 194%4 studies (-/4)100.0 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.